What is CagriSema?
CagriSema is Novo Nordisk's answer to the next generation of GLP-1 class therapeutics — a fixed-dose combination of semaglutide (their proven GLP-1 receptor agonist) with cagrilintide, a long-acting amylin analog. Where retatrutide (Eli Lilly's triple agonist) adds GIP and glucagon receptor agonism to GLP-1, CagriSema takes a different route: pairing GLP-1 with amylin, a pancreatic hormone that works synergistically through complementary and non-overlapping mechanisms.
Amylin is co-secreted with insulin by pancreatic beta cells and acts through its own receptors in the hypothalamus and brainstem. Its effects complement GLP-1: GLP-1 primarily suppresses appetite via hypothalamic pathways; amylin slows gastric emptying more potently and for longer than GLP-1 alone, reduces postprandial glucagon, and promotes satiety via area postrema signaling. The combination produces additive or synergistic effects through independent receptor systems.
Phase III REDEFINE 1 (2024/2025): 3,417 participants. CagriSema produced 22.7% mean weight loss at 68 weeks vs. 8.0% for semaglutide alone and 1.8% for placebo. 40.9% achieved ≥25% weight loss. These results position CagriSema as competitive with retatrutide and far superior to semaglutide alone — arriving from a different mechanistic direction.
How it works
GLP-1 Receptor Agonism (Semaglutide Component)
The semaglutide component provides the well-characterized GLP-1 mechanism: central appetite suppression via hypothalamic GLP-1R, slowed gastric emptying, glucose-dependent insulin secretion, and reduced glucagon. This is the proven foundation that the combination builds upon.
Amylin Receptor Agonism (Cagrilintide Component)
Amylin acts through amylin receptors (calcitonin receptor + receptor activity-modifying proteins) primarily in the area postrema and nucleus of the solitary tract — distinct from GLP-1R's primary sites. Amylin receptor activation: slows gastric emptying (more potently and durably than GLP-1 alone), reduces postprandial glucagon, and promotes gut-brain satiety signaling. Cagrilintide is a modified amylin analog with a half-life supporting once-weekly dosing.
How CagriSema Differs from Retatrutide
Retatrutide adds GIP and glucagon receptor agonism to GLP-1 — the glucagon arm specifically increases energy expenditure and drives direct lipolysis. CagriSema adds amylin receptor agonism to GLP-1 — the amylin arm specifically enhances caloric intake reduction through gastric emptying and brainstem satiety. Both produce similar weight loss outcomes, but through different mechanisms. No head-to-head data between the two exists yet.
What the research shows
CagriSema vs. semaglutide for weight loss (REDEFINE 1)
Garvey WT et al.
REDEFINE 1: 3,417 adults with obesity over 68 weeks. CagriSema (cagrilintide + semaglutide) produced ~20.4% mean weight loss vs ~3.0% for placebo (a ~17-point difference), with more participants reaching the ≥25% weight-loss mark — outperforming the individual components. GI effects (nausea, vomiting, diarrhea) were the main adverse events (~80% vs ~40% on placebo), mostly mild-to-moderate and transient.
View on PubMed →Once-weekly cagrilintide for weight management — Phase 2 dose-finding
Lau DCW et al.
706 adults with overweight or obesity, 26 weeks. Cagrilintide monotherapy across 0.3–4.5 mg produced dose-dependent weight loss of 6.0–10.8% vs. 3.0% for placebo, with the top dose (4.5 mg) beating liraglutide 3.0 mg (10.8% vs. 9.0%). Established cagrilintide's standalone profile before the CagriSema combination.
View on PubMed →What the community reports
CagriSema's community is primarily people following the next-generation metabolic therapeutics space closely — those who have used semaglutide or tirzepatide and are tracking what comes next. Because it's investigational and not widely available off-label yet, community use is less extensive than for retatrutide. The comparison to retatrutide is the dominant community conversation — both produce ~22–29% weight loss through different mechanisms. Some users are running self-constructed combinations of compounded cagrilintide with their existing semaglutide protocols.
Common misconceptions
"CagriSema and retatrutide are the same thing."
Both are next-generation metabolic compounds beyond semaglutide, but mechanistically different. CagriSema = GLP-1 + amylin. Retatrutide = GLP-1 + GIP + glucagon. The weight loss outcomes are similar; the mechanistic paths are different. Retatrutide's glucagon arm drives energy expenditure; CagriSema's amylin arm drives gastric emptying control and brainstem satiety.
"CagriSema is just semaglutide with an add-on."
The 22.7% vs. 8.0% weight loss in REDEFINE 1 shows CagriSema meaningfully outperforms semaglutide alone — nearly three times the weight loss. The amylin component is not a minor addition; it's a significant mechanistic contribution through independent receptor systems.
"Phase III success means FDA approval is imminent."
Phase III success is necessary but not sufficient for approval. Novo Nordisk still needs to file a BLA and FDA needs to review it. Earliest plausible approval is 2026–2027 — soon, but not immediate.
COMPARE — NEXT GENERATION METABOLIC
Retatrutide — GLP-1/GIP/glucagon triple agonist, 28.7% weight loss (Phase 3). Different mechanism, similar headline outcomes. Tirzepatide and Semaglutide — currently approved options.
Open PepperLedger to track your GLP-1 combination protocol →
Free to join. No credit card. Track your metabolic protocol and ask the Researcher.
Free to join · No credit card · 23-day Pro trial included
Registered trials and extra catalog links. These are not Study cards — a registry page is not proof of efficacy.
- ClinicalTrials.gov · completed · NCT05813925CagriSema weight loss (East Asia)
- ClinicalTrials.gov · completed · NCT06403761CagriSema insulin effects in type 2 diabetes